Abstract:Abstract Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, which are a dominant cause of death worldwide. Before being allowed to be used and distributed, every new potentially therapeutic compound must be strictly validated during preclinical and clinical trials. The preclinical studies usually involve the in vitro and in vivo evaluation. Due to the increasing reporting of discrepancy in drug effects in animal and humans and the requirement to reduce the number of animals used in research, improvement of in vitro models based on human cells is indispensable. Primary cardiac cells are difficult to access and maintain in cell culture for extensive experiments; therefore, the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) became an excellent alternative. This technology enables a production of high number of patient- and disease-specific cardiomyocytes and other cardiac cell types for a large-scale research. The drug effects can be extensively evaluated in the context of electrophysiological responses with a use of well-established tools, such as multielectrode array (MEA), patch clamp, or calcium ion oscillation measurements. Cardiotoxicity, which is a common reason for withdrawing drugs from marketing or rejection at final stages of clinical trials, can be easily verified with a use of hiPSC-CM model providing a prediction of human-specific responses and higher safety of clinical trials involving patient cohort. Abovementioned studies can be performed using two-dimensional cell culture providing a high-throughput and relatively lower costs. On the other hand, more complex structures, such as engineered heart tissue, organoids, or spheroids, frequently applied as co-culture systems, represent more physiological conditions and higher maturation rate of hiPSC-derived cells. Furthermore, heart-on-a-chip technology has recently become an increasingly popular tool, as it implements controllable culture conditions, application of various stimulations and continuous parameters read-out. This paper is an overview of possible use of cardiomyocytes and other cardiac cell types derived from hiPSC as in vitro models of heart in drug research area prepared on the basis of latest scientific reports and providing thorough discussion regarding their advantages and limitations.

Heart rhythm in vitro: measuring stem cell-derived pacemaker cells on microelectrode arrays

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Novel high-dense microelectrode array based multimodal bioelectronic monitoring system for cardiac arrhythmia re-entry analysis

Multi-Channel System for Analysis of Cardiac Rhythmicity and Conductivity in Vitro

Simultaneous study of mechanobiology and calcium dynamics on hESC-derived cardiomyocytes clusters

Simulation of cardiac arrhythmias in human induced pluripotent stem cell-derived cardiomyocytes

Safety pharmacology studies using EFP and impedance

Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays

A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids

Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological function

Simultaneous electromechanical monitoring in engineered heart tissues using a mesoscale framework

Multifunctional 3D Electrode Platform for Real-Time in Situ Monitoring and Stimulation of Cardiac Tissues

A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling

Current-Controlled Electrical Point-Source Stimulation of Embryonic Stem Cells

Genetically engineered cardiac pacemaker: stem cells transfected with HCN2 gene and myocytes - a model

Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function

Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell–Derived Ventricular Cardiomyocytes Using Multielectrode Array

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research

CardioMEA: comprehensive data analysis platform for studying cardiac diseases and drug responses